(8-chloro-quinolin-2-yl)-(4-methyl-pyridin-2-yl)-amine | 1258420-47-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (8-chloro-quinolin-2-yl)-(4-methyl-pyridin-2-yl)-amine
• 英文别名: 8-chloro-N-(4-methyl-2-pyridyl)quinolin-2-amine；8-chloro-N-(4-methylpyridin-2-yl)quinolin-2-amine
• CAS: 1258420-47-1
• 化学式: C₁₅H₁₂ClN₃
• 分子量: 269.733
• InChiKey: FELITWFKOKSVOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-4-甲基吡啶 、 2,8-二氯喹啉 在 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 叔丁醇 为溶剂， 反应 20.0h， 以1.3 g的产率得到(8-chloro-quinolin-2-yl)-(4-methyl-pyridin-2-yl)-amine
  参考文献：
  名称：

  [EN] BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES
  [FR] COMPOSÉS BICYCLIQUES UTILES POUR LE TRAITEMENT DE MALADIES CAUSÉES PAR DES RÉTROVIRUS

  摘要：

  本文描述了一种预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病的方法。在某些方面，所述方法包括将化合物(I)与需要其治疗的细胞接触，其中(II)表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟代烷基团、(C1-C3)氟代烷氧基团、-NO2基团、-NR1R2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(C1-C3)烷基团、羟基基团、-COOR1基团、-NO2基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(C1-C3)氟代烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，以预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病，其中逆转录病毒感染不是HIV，由逆转录病毒感染引起的疾病不是艾滋病。

  公开号：

  WO2015001518A1

文献信息

• QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：ABIVAX

  公开号：US20170204063A1

  公开（公告）日：2017-07-20

  The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxy! group, a —COOR 1 group, a —NO2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C 1 -C3)fluoroalkyl group, a —O—P(=O)—(OR 3 XOR 4 ) group, a (C 1 -C 4 )alkoxy group and a —CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease.

  本发明涉及一种化合物，其化学式为（I），其中：化学式（II）表示芳香环，其中V为C或N，当V为N时，Q为N或O，但当Q为O时，R″不存在；R′独立表示氢原子或从（C1-C3）烷基，卤素原子，羟基，—COOR1基团，—NO2基团，—NR1R2基团，吗啉基或吗啉基团，N-甲基哌嗪基团，（C1-C3）氟代烷基，—O—P（=O）—（OR3XOR4）基团，（C1-C4）烷氧基和—CN基团中选择的一种基团，并且还可以是选择于（IIa），（IIIa）或其任何药学上可接受的盐，用于治疗和/或预防炎症性疾病。
• COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA
  申请人：Tazi Jamal

  公开号：US20120329796A1

  公开（公告）日：2012-12-27

  The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO2 group, a —NRiR2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n′ is 1 or 2, R′ is a hydrogen atom, a halogen atom or a group chosen among a (Ci-C3)alkyl group, a hydroxyl group, a —COOR 1 group, a —NO2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a (C 1 -C 4 )alkoxy group and a —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中：表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟烷基团、(C1-C3)氟烷氧基团、-NO2基团、-NRiR2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被一个羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(Ci-C3)烷基团、羟基基团、-COOR1基团、-NO2基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(Ci-C3)氟烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，用作预防、抑制或治疗与早衰有关的病理或非病理状态的药剂。其中一些化合物是新的，也是本发明的一部分。
• Compounds useful to treat premature aging and in particular progeria
  申请人：Splicos Sas

  公开号：EP2261214A1

  公开（公告）日：2010-12-15

  The present invention relates to a compound of formula (I): wherein: means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, i.e. forms respectively a pyridazine, a pyrimidine or a pyrazine group, R independently represents a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group, a -CN group, a -COOH group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a -NO2 group, a -NR1R2 group and a (C1-C3)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, n is 1 or 2, R' is a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxy group, a -COOH group and a -CN group, R" is a hydrogen atom or a (C1-C4)alkyl group, Z is N or C, Y is N or C, X is N or C, W is N or C, and wherein at most two of the groups Z, Y, X and W are N, or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.

  本发明涉及一种式 (I) 的化合物： 其中 指一个芳香环，其中 V 是 C 或 N，当 V 是 N 时，V 位于 Z 的正位、偏位或对位，即分别形成哒嗪、嘧啶或吡嗪基团、 R 独立地代表氢原子、卤素原子或选自 (C1-C3) 烷基、-CN 基团、-COOH 基团、(C1-C3) 氟烷基、(C1-C3) 氟烷氧基、-NO2 基团、-NR1R2 基团和 (C1-C3) 烷氧基的基团、 R1 和 R2 独立地为氢原子或 (C1-C3) 烷基、 n 为 1 或 2、 R'是氢原子或选自(C1-C3)烷基、卤素原子、羟基、-COOH 基和-CN 基的基团、 R "是氢原子或 (C1-C4) 烷基、 Z 是 N 或 C、 Y 是 N 或 C X 是 N 或 C W 是 N 或 C、 其中 Z、Y、X 和 W 至多有两个基团是 N、 或其任何一种药学上可接受的盐、 用于预防、抑制或治疗与过早衰老有关的病理或非病理状况。
• New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
  申请人：Splicos

  公开号：EP2266972A1

  公开（公告）日：2010-12-29

  The present invention relates to a compound of the formula I; a pharmaceutical composition comprising at least one such compound; and the use of such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

  本发明涉及一种式 I 的化合物；一种包含至少一种此类化合物的药物组合物；以及使用此类化合物制备药物，以治疗受试者因至少一种剪接异常而导致的遗传疾病。
• Quinoline derivatives for use in the treatment or prevention of viral infection
  申请人：ABIVAX

  公开号：EP3058940A1

  公开（公告）日：2016-08-24

  The present invention relates to A quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.

  本发明涉及一种式 (I) 的喹啉衍生物 或其任何一种药学上可接受的盐，或其任何一种代谢物、 用于治疗或预防患者的病毒感染，特别是 HIV 感染或 HIV 相关疾病；当病毒载量低或检测不到；和/或 CD4+ 细胞计数水平保持或恢复时，终止上述治疗。 本发明进一步涉及权利要求 1 所定义的式 (I) 喹啉衍生物或其任何一种药学上可接受的盐和代谢物，用于治疗或预防病毒感染，特别是艾滋病病毒感染或患者的艾滋病病毒相关病症，之前的抗逆转录病毒治疗效果无效或下降，本发明还涉及如上定义的式 (I) 喹啉衍生物、或其任何一种药学上可接受的盐和代谢物，用于治疗或预防病毒感染，特别是患者的 HIV 感染或 HIV 相关病症，其中患者感染的是耐药病毒株，尤其是耐药 HIV 株。